Related Experiment Video
Updated: Jul 13, 2025
A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice
Published on: June 22, 2022
Cerebrolysin for acute ischaemic stroke
Liliya Eugenevna Ziganshina1,2,3, Tatyana Abakumova4, Dilyara Nurkhametova1
1Centre for Knowledge Translation, Federal State Budgetary Educational Institution of Continuing Professional Education "Russian Medical Academy of Continuing Professional Education", The Ministry of Health of the Russian Federation (RMANPO), Moscow, Russian Federation.
Cerebrolysin, a peptide mixture, likely offers no significant benefit for acute ischemic stroke patients regarding mortality or serious adverse events. However, there is a potential increase in non-fatal serious adverse events, warranting caution.
Area of Science:
- Neurology
- Pharmacology
- Clinical Trials
Background:
- Cerebrolysin, a peptide and amino acid mixture from porcine brain, is used for neuroprotection.
- It is widely administered for acute ischemic stroke in several countries.
- This review is an update of previous analyses from 2010 and 2020.
Conclusions:
- Cerebrolysin and similar peptide mixtures likely provide no significant benefit for preventing all-cause death in acute ischemic stroke.
- Cerebrolysin appears to have no beneficial effect on the total number of serious adverse events.
- Evidence suggests a potential increase in non-fatal serious adverse events associated with Cerebrolysin use.
